Xeris Biopharma Holdings (XERS) Current Assets (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Current Assets came in at $251.7 million in Q1 2026, up 53.94% YoY from $163.5 million in Q1 2025, and up 4.73% on a QoQ basis from $240.3 million in Q4 2025.
Xeris Biopharma Holdings (XERS) Current Assets (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 7 years of Current Assets data on file, last reported at $251.7 million in Q1 2026.
- Quarterly Current Assets rose 53.94% year-over-year to $251.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $251.7 million (up 53.94% YoY) and the FY2025 annual result came in at $240.3 million, up 43.33% from the prior year.
- Current Assets rose to $251.7 million in Q1 2026, from $240.3 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $251.7 million in Q1 2026 to a low of $148.9 million in Q3 2022.
- A 5-year average of $179.4 million and a median of $167.7 million in 2024 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2023 — Current Assets dropped 16.35% — and 2026, when it soared 53.94%.
- Tracing XERS's Current Assets over 5 years: stood at $186.8 million in 2022, then decreased by 16.35% to $156.3 million in 2023, then gained by 7.29% to $167.7 million in 2024, then jumped by 43.33% to $240.3 million in 2025, then gained by 4.73% to $251.7 million in 2026.
- The last three Current Assets figures came in at $251.7 million (Q1 2026), $240.3 million (Q4 2025), and $224.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 5.76 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 13.76 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 6.36 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 19.76 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 3.48 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 10.06 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.64 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 3.80 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 3.22 Bn |
| 10 | Xeris Biopharma Holdings | 1.48 Bn | 1.36 Bn | 79.59 Mn | 274.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 274.76 Mn |
| Mar 31, 2026 | 251.68 Mn |
| Dec 31, 2025 | 240.31 Mn |
| Sep 30, 2025 | 224.02 Mn |
| Jun 30, 2025 | 185.58 Mn |
| Mar 31, 2025 | 163.49 Mn |
| Dec 31, 2024 | 167.66 Mn |
| Sep 30, 2024 | 162.80 Mn |
| Jun 30, 2024 | 170.34 Mn |
| Mar 31, 2024 | 173.28 Mn |
| Dec 31, 2023 | 156.26 Mn |
| Sep 30, 2023 | 158.05 Mn |
| Jun 30, 2023 | 155.74 Mn |
| Mar 31, 2023 | 165.51 Mn |
| Dec 31, 2022 | 186.82 Mn |
| Sep 30, 2022 | 148.92 Mn |
| Jun 30, 2022 | 161.21 Mn |
| Mar 31, 2022 | 177.55 Mn |
| Dec 31, 2021 | 142.60 Mn |
| Sep 30, 2021 | 124.37 Mn |